Unique ID issued by UMIN | UMIN000005275 |
---|---|
Receipt number | R000006234 |
Scientific Title | Effect of cefepime (CFPM) or meropenem (MEPM) for febrile neutropenia patients with lung cancer. Randomized phase II study. |
Date of disclosure of the study information | 2011/03/18 |
Last modified on | 2013/03/26 14:02:30 |
Effect of cefepime (CFPM) or meropenem (MEPM) for febrile neutropenia patients with lung cancer. Randomized phase II study.
Febrile neutropenia patients with lung cancer. CFPM vs MEPM
Effect of cefepime (CFPM) or meropenem (MEPM) for febrile neutropenia patients with lung cancer. Randomized phase II study.
Febrile neutropenia patients with lung cancer. CFPM vs MEPM
Japan |
Febrile neutropenia
Pneumology |
Malignancy
NO
The objective of this study is to determine the efficacy and safety of cefepime or meropenem for febrile neutropenia in lung cancer patients by prospective randomized study.
Efficacy
Response rate
Defervescence at 72 hours, 7 days, 14 days
Safety
Interventional
Parallel
Randomized
Cluster
Open -no one is blinded
Uncontrolled
NO
YES
Institution is considered as adjustment factor in dynamic allocation.
Central registration
2
Treatment
Medicine |
Administration of antibiotics (Cefepime)
Administration of antibiotics (Meropenem)
20 | years-old | <= |
Not applicable |
Male and Female
1. Informed consent is obtained
2. Patient who is judged as an appropriate case by the doctor in charge
3. At least 20 years of age
4. Patient who had lung cancer accompanied by chemotherapy-induced neutropenia with a polymorphonuclear neutrophil count of <1000/mm3 and a temperature of >= 37.5
1. Patient who is too severely ill
2. A history of cardiac failure, renal failure, or liver damage.
3. A known history of hypersensitivity to cephalosporins
4. A known history of allergy
5. Patient who demonstrated positive for skin reaction test ( if skin reaction test was done)
6. Patient who is not evaluated for response
7. Pregnant or lactating women.
8. Patient administered with sodium valproate
9. Patients administered with prohibiting medication (such as other antibiotics, gamma-globulin, corticosteroid, furosemide)
10.patient who is judged as an inappropriate case by the doctor in charge
46
1st name | |
Middle name | |
Last name | Masaki Fujita |
Fukuoka University
Department of Respiratory Medicine
7-45-1 Nanakuma, Jonanku, Fukuoka
092-801-1011
1st name | |
Middle name | |
Last name | Junji Uchino |
Fukuoka University
Department of Respiratory Medicine
7-45-1 Nanakuma, Jonanku, Fukuoka
092-801-1011
uchino@fukuoka-u.ac.jp
LOGIK(Lung oncology group in Kyushu)
Clinical Research Support Center Kyushu
Non profit foundation
JAPAN
NO
福岡大学病院(福岡県)
済生会飯塚嘉穂病院(福岡県)
飯塚病院(福岡県)
九州大学(福岡県)
済生会福岡総合病院(福岡県)
産業医科大学(福岡県)
浜の町病院(福岡県)
福岡大学筑紫病院(福岡県)
国立病院機構福岡病院(福岡県)
原三信病院(福岡県)
大分大学(大分県)
熊本大学(熊本県)
健康保険諫早総合病院(長崎県)
長崎大学病院(長崎県)
国立病院機構岩国医療センター(山口県)
2011 | Year | 03 | Month | 18 | Day |
Unpublished
Completed
2010 | Year | 12 | Month | 04 | Day |
2011 | Year | 01 | Month | 01 | Day |
2013 | Year | 01 | Month | 01 | Day |
2011 | Year | 03 | Month | 18 | Day |
2013 | Year | 03 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006234